News: immunotherapy
SAiGENCI researcher awarded funding in latest MRFF round
A SAiGENCI project using nanotechnology has received funding in the latest round of Medical Research Future Fund (MRFF) Early-to-Mid Career Researchers funding.
[Read more about SAiGENCI researcher awarded funding in latest MRFF round]
SAiGENCI recruit recognised with prestigious award
Professor Jenkins has been appointed as the Program Head for the Tumour Inflammation and Immunotherapy Program at the South Australian ImmunoGENomics Cancer Institute (SAiGENCI), which operates within the University of Adelaide’s Faculty of Health and Medical Sciences, and is supported by an alliance with the Central Adelaide Local Health Network (CALHN).
[Read more about SAiGENCI recruit recognised with prestigious award]
